Our Story

The biotechnology industry is still in its infancy today. The total of all products created by the industry can be traced back to just a handful of genes representing less than 1% of genes known to mankind. The remaining 99% of genes remain unsolved. These are likely to hold the keys to treating some of the most pressing diseases faced by mankind. Over the recent years, the next-generation sequencing revolution has led to a significant understanding of biology, disease processes, and fundamental biochemistry and the composition of the genes. Unprecedented insight into the diversity of individuals and their biochemical makeup has occurred over the past few years to allow disease to be studied at an accelerated manner. The availability of this information allows for unprecedented selection of novel targets and a significant opportunity to generate novel therapies to treat disease. Historically, creating the byproducts from genes has been a major bottleneck. Our Diversimmune platform overcomes such limitations to allow the study of genes at industry leading speeds to create novel, breakthrough medicines.

Our People

Ian Chan

Chairman, CEO, Founder

Previously: Co-founder, CFO of U.S. Genomics; private equity at Morgan Stanley, Bear Stearns. MBA Harvard Business School; AB Brown University, Pre-medical studies.

Eugene Chan, M.D.

Co-founder, Vice Chairman

CEO, DNA Medicine Institute; US Genomics; MD Harvard Medical School HST; AB Harvard.

Adam Mostafa


Previously Cantor Fitzgerald, Needham, CRT, AQR, Citi. AB Brown University, Mathematical Economics

James Yang, Ph.D.

President, China Division

Previously Qilu, Sanofi/Genzyme, MedImmune, Abbvie. PhD, Illinois Institute of Technology.

Gavin MacBeath


Previously Co-Founder Merrimack, SVP of Discovery/Head of Translational Medicine; Faculty of Harvard University. Ph.D., Scripps; University of Manitoba BS

Qi Xue, M.D., Ph.D.

Senior Director, Therapeutics

Previously: Imclone/Eli Lilly. Ph.D. University of Gunma

Jessie Wong, Ph.D.

Director, Business Development

PhD Massachusetts Institute of Technology; BS University of California, San Diego.

Scientific Advisory Board

Eugene Chan, M.D.

Co-founder, Vice Chairman

CEO, DNA Medicine Institute; US Genomics; MD Harvard Medical School HST; AB Harvard.

Bob Langer, Ph.D.

Institute Professor at MIT with over 840 written articles and over 500 issued or pending patents. Founder of AIR, Momenta, Acusphere, Tempo Pharma, others.

Laurie Glimcher, M.D.

Dean of Weill Cornell Medical College. Member of the National Academy of Sciences. Board member Bristol-Myers Squibb and Waters Corp.

Josh Labaer, M.D., Ph.D.

Virginia G. Piper Chair in Personalized Medicine at ASU’s The BioDesign Institute. Former Director of the Harvard Institute of Proteomics; Professor Harvard Medical School.

Rita Colwell, Ph.D.

Chairman, Canon Life Sciences; Former Director NSF, appointed by Bill Clinton.

David Sachs, M.D.

Professor at Harvard Medical School in Immunology.

Ronald Levy, M.D.

Professor of Medicine, Director of the Lymphoma Program, Former Chief of the Division of Oncology at Stanford University.

Shiv Pillai, M.D., Ph.D.

Professor of Medicine, Harvard Medical School

Join our Team

We welcome you to learn more about joining us! We offer a fast-paced and dynamic team-based work environment.

Learn More →


May 20 2016

Abpro Announces Agreements with Two Boston Hospitals

Abpro, an integrated life science company at the forefront of synthetic biology, today announced co-development agreements with Massachusetts General Hospital (MGH) and Brigham and Women’s Hospital (BWH), two of the country’s leading academic medical centers

Read More →

Apr 25 2016

Abpro Announces Investment and Partnership with Essex Bio

Abpro, an integrated life science company at the forefront of synthetic biology, today announced a partnership with Essex Bio, a China-based biopharmaceutical company.

Read More →

Oct 10 2014

Abpro Co-Founder Eugene Chan Wins Nokia Sensing XChallenge

Chan led a team from DNA Medicine Institute (DMI), a Cambridge-based medical technology incubator and lab, that developed rHEALTH, a compact portable device that can run hundreds of clinical lab tests on a single drop of blood with gold standard accuracy.

Read More →


Sep 13 – 16, 2016

BioPharma America 9th Annual Partnering Conference

Marriott Copley Place, 110 Huntington Ave, Boston, MA

Sep 19 – 21, 2016

FierceBiotech Drug Development Forum

Intercontinental Boston, 510 Atlantic Ave, Boston, MA 02210

Oct 31 – 4, 2016

PEGS Europe

Lisbon, Portugal

Our Partners

Receive updates from Abpro

Contact us →